Liquidia (LQDA) Cash from Financing Activities (2020 - 2026)
Liquidia (LQDA) recorded quarterly Cash from Financing Activities of -$18.1 million in Q1 2026, down 157.11% quarter-over-quarter from -$7.0 million in Q4 2025, and down 174.33% on a YoY basis from $24.3 million in Q1 2025.
Liquidia (LQDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Liquidia's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$18.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 174.33% year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at $17.4 million (down 85.43% YoY), while the FY2025 annual figure was $59.7 million, down 69.32% from the prior year.
- Cash from Financing Activities was -$18.1 million for Q1 2026 at Liquidia, down from -$7.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $99.7 million in Q1 2024 to a low of -$18.1 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $20.3 million across 5 years, with a median of $10.0 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 41377.19% in 2023, then tumbled 205.84% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $57000.0 in 2022, then jumped by 41377.19% to $23.6 million in 2023, then slumped by 109.71% to -$2.3 million in 2024, then sank by 205.84% to -$7.0 million in 2025, then sank by 157.11% to -$18.1 million in 2026.
- The last three Cash from Financing Activities figures came in at -$18.1 million (Q1 2026), -$7.0 million (Q4 2025), and -$5.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | -11.62 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -77.88 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.05 Mn |
| Mar 31, 2026 | -18.05 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Jun 30, 2025 | 47.71 Mn |
| Jun 30, 2025 | 47.71 Mn |
| Mar 31, 2025 | 24.29 Mn |
| Mar 31, 2025 | 24.29 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Sep 30, 2024 | 98.10 Mn |
| Sep 30, 2024 | 98.10 Mn |
| Jun 30, 2024 | -814,000.00 |
| Jun 30, 2024 | -814,000.00 |
| Mar 31, 2024 | 99.67 Mn |
| Mar 31, 2024 | 99.67 Mn |
| Dec 31, 2023 | 23.64 Mn |
| Dec 31, 2023 | 23.64 Mn |